Home Tags Pfizer

Tag: Pfizer

Astellas Pharma. Exhibition booth during the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

ASCO 2024: Astellas to Showcase Scientific Advancements

During the upcoming 2024 annual meeting of the American Society of Clinical Oncology (ASCO) Annual Meeting, been held from May 31st - June 4th, Astellas...

Supplemental Biologics License Application for Tisotumab Vedotin Accepted for FDA Priority...

The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for tisotumab vedotin (Tivdak®; Genmab and Pfizer) for the treatment of patients with recurrent or metastatic cervical cancer.

Pfizer to Acquire Seagen for US $ 43 Billion

Pfizer and Seagen have entered into a definitive merger agreement under which Pfizer will acquire Seagen for US $229 in cash per Seagen share...

FDA Approval for Gemtuzumab Ozogamicin: Reintroduction Based on Favorable Risk:Benefit Profile

The U.S. Food and Drug Administration (FDA) has approved gemtuzumab ozogamicin (Mylotarg™, previously known as CMA-676; Wyeth Pharmaceuticals, a subsidiary of Pfizer) for the...

U.S. FDA Approves Inotuzumab Ozogamicin for Treatment of Patients with R/R...

The United States Food and Drug Administration (FDA) approved inotuzumab ozogamicin (Besponsa™, Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.) for the treatment of...

Antibody-drug Conjugates: Technologies and Global Markets

Less than 3 decades old, antibody-drug conjugate or ADC-technology is a relatively new.  Due to many technological advances, recognition of appropriate target antigens, success...

Inotuzumab ozogamicin Approved in the EU for Adult Patients with Relapsed...

The European Commission has approved inotuzumab ozogamicin (Besponsa®; Pfizer) as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute...

PF 06263507: Targeting Treatment-resistant Childhood Leukemia

Researchers at The University of Manchester have discovered that 5T4, a transmembrane glycoprotein overexpressed by a variety of cancers and correlated with increased invasiveness,...

Trial of High Efficiency TFF Capsule Prototype for ADC Purification

Antibody-drug conjugates (ADCs) are an emerging class of highly targeted cancer therapies in which a monoclonal antibody is chemically conjugated to a cytotoxic drug...

Pfizer Resubmits Application for Gemtuzumab Ozogamicin to European and American Regulators

In late January 2017 Pfizer's Biologics License Application (BLA) for gemtuzumab ozogamicin (Mylotarg®; previously known as CMA-676) was accepted for filing by the U.S....

X